Advanced Analytics. Intelligent Insights.

Your medical imaging partner, we support biopharmaceutical companies across all phases of CNS clinical research.

logo-outline

The impact of diversity on Alzheimer's disease clinical trial design

Lammert Albers, Chief Commercial Officer of the Global Alzheimer's Platform Foundation talks with John Dwyer, President of the foundation, and our Chief Scientific Officer, Robin Wolz about the impact of this study diversity on current and future research and the opportunities at hand at the upcoming CTAD Clinical Trials on Alzheimer's Disease 2023 conference in Boston.

READ MORE

Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants

Summary: For HD-ISS Stage 2 and Stage 3 participants, whole-brain volume shows significant association with clinical change for all four clinical variables examined here. For caudate and putamen volume, the association depended on the clinical variable. Our results provide further evidence on the use of volume change as a surrogate endpoint.

READ MORE

Alzheimer's Disease: The Role of Cutting-Edge Neuroimaging Techniques

  Alzheimer's disease is a complex neurodegenerative disorder that affects millions of people worldwide. While there is no cure for the disease, ongoing research efforts have led to significant advancements in our understanding of the underlying mechanisms that drive the disease.

READ MORE

Consultancy

We can work with you on the selection and use of medical imaging and digital biomarkers for your drug development programs, directly and as part of collaborative consortia.

Read more

Early Phase

We are experts in the definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.



Read more

Late Phase

Our global network of over 2,000 imaging centers across 75 countries ensures large-scale trials can be set up quickly and efficiently, while our custom TrialTracker platform delivers highly reliable, regulatory compliant data.

Read more

Post-Marketing

We understand the challenges of extended longitudinal studies. We support you to monitor patient safety and drug utilization for ongoing optimization of patient pathways post-marketing.

Read more

Specialist Therapeutic Focus

We have focused exclusively on neurological disorders since 2004, and our growing team are renowned experts in CNS therapeutics. We combine specialist neuroscience knowledge, highly curated neurological patient data and proven pipeline algorithms to accurately measure brain biomarkers. 

Our world-class therapeutic expertise, breakthrough technology and analytics, and operational excellence makes us the partner of choice for imaging biomarker solutions in CNS clinical trials.

The diseases we work on include:

Scanner icon 2

Imaging Biomarkers

Scanner icon 2

Imaging Biomarkers

We are at the forefront of developing and validating unique neuroimaging methods and MRI and PET image analysis techniques. This enables us to provide you with accurate, rich structural and functional information.

AI icon 2

Analytics & AI

AI icon 2

Analytics & AI

In neuroscience, AI has applications across the entire spectrum of understanding and treating disease. Our sophisticated AI technology and analytics support your clinical development programmes by interpreting complex patient data into valuable insight.

Data platforms icon 2

Data Platforms

Data platforms icon 2

Data Platforms

Our fully compliant image and digital data management provides everything you need to manage complex data workflows in CNS clinical trials. Our secure online digital platform supports your clinical decision-making, from patient selection to post-marketing surveillance.

Get the latest content from IXICO

Sign up below and we'll send you the latest insight, knowledge and innovations from IXICO to your inbox.

Subscribe to content